Jasper Therapeutics, Inc. (JSPR) shareholders
JSPRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$13.37−1.39 (-9.42%)
Close on Nov 12, 2026Market cap $444.88MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
36.1%
12M of 33M shares
Institutional holders
45
3 new, 16 sold out
Net institutional buying
-4M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Velan Capital Investment Management LP Joint filing with Velan Capital Management LLC (9.90%), Morgan Adam (9.90%) and 3 more | 3,363,347 | 9.90% | 13G (passive) | Aug 17, 2026 |
| Morgan Adam Joint filing with Velan Capital Investment Management LP (9.88%), Velan Capital Management LLC (9.88%) and 3 more | 3,349,547 | 9.88% | 13D (active) amendment | Jul 16, 2026 |
| Velan Capital Management LLC Joint filing with Velan Capital Investment Management LP (9.60%), Morgan Adam (9.60%) and 3 more | 2,668,395 | 9.60% | 13D (active) amendment | Sep 19, 2025 |
| Bank Of America Corp /De/ | 2,133,861 | 6.40% | 13G (passive) | Sep 30, 2026 |
| T. Rowe Price Investment Management, Inc. | 2,057,612 | 7.10% | 13G (passive) | Sep 30, 2025 |
| Goldman Sachs & Co. LLC Joint filing with The Goldman Sachs Group, Inc. (6.30%) | 1,764,848 | 6.30% | 13G (passive) | Dec 31, 2025 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (5.80%), Israel A. Englander (5.80%) and 1 more | 1,629,013 | 5.80% | 13G (passive) | Feb 18, 2026 |
| Soleus GP LLC Joint filing with Soleus Capital Management, L.P. (9.96%), Guy Levy (9.96%) and 3 more | 1,494,420 | 9.96% | 13G (passive) amendment | Dec 31, 2024 |
| Anders Hove | 1,486,492 | 5.30% | 13G (passive) amendment | Jan 23, 2026 |
| Guy Levy Joint filing with Soleus Capital Management, L.P. (9.00%), Soleus GP, LLC (9.00%) and 3 more | 1,343,665 | 9.00% | 13G (passive) amendment | Sep 30, 2024 |
| Kingdon Capital Management, L.L.C. Joint filing with Mark Kingdon (5.10%) | 765,000 | 5.10% | 13G (passive) | Jul 3, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of JSPR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Velan Capital Investment Management LP | 2,668,395 | 8.02% | $1.12M | – | 0.68% |
| Acorn Capital Advisors, LLC | 1,438,159 | 4.32% | $604.03K | +26,667 | 0.16% |
| Kingdon Capital Management, L.L.C. | 1,352,106 | 4.06% | $569.24K | – | 0.06% |
| Vanguard Capital Management LLC | 1,172,021 | 3.52% | $493.42K | −576 | 0.00% |
| Rock Springs Capital Management LP | 1,100,726 | 3.31% | $463.41K | – | 0.02% |
| Carlyle Group Inc. | 1,066,189 | 3.20% | $448.87K | – | 0.00% |
| Gsa Capital Partners Llp | 534,697 | 1.61% | $225.00K | +515,613 | 0.01% |
| Millennium Management LLC | 486,933 | 1.46% | $205.00K | −1,130,598 | 0.00% |
| Lion Point Capital, LP | 465,000 | 1.40% | $195.77K | – | 0.94% |
| Geode Capital Management, LLC | 263,808 | 0.79% | $111.09K | −53,869 | 0.00% |
| Renaissance Technologies LLC | 237,900 | 0.71% | $100.16K | +60,400 | 0.00% |
| BlackRock, Inc. | 169,627 | 0.51% | $71.41K | −72,434 | 0.00% |
| Vanguard Fiduciary Trust Co | 149,943 | 0.45% | $63.13K | – | 0.00% |
| ADAR1 Capital Management, LLC | 140,000 | 0.42% | $58.94K | – | 0.00% |
| Quarry LP | 131,529 | 0.40% | $55.37K | – | 0.00% |
| Jane Street Group, LLC | 101,743 | 0.31% | $42.83K | +80,328 | 0.00% |
| UBS Group AG | 58,759 | 0.18% | $24.74K | −22,358 | 0.00% |
| Jain Global LLC | 51,185 | 0.15% | $21.55K | +33,163 | 0.00% |
| Osaic Holdings, Inc. | 45,850 | 0.14% | $19.30K | +5,000 | 0.00% |
| State Street Corp | 44,699 | 0.13% | $18.82K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 45 | 12M | 36.1% | 3 / 9 | 14 / 16 | 1M | 5M |
| Q1 2026 | 58 | 16M | 47.5% | 13 / 15 | 13 / 9 | 4M | 7M |
| Q4 2025 | 55 | 20M | 58.9% | 11 / 23 | 11 / 15 | 6M | 6M |
| Q3 2025 | 60 | 20M | 60.6% | 15 / 16 | 19 / 20 | 10M | 2M |
| Q2 2025 | 65 | 13M | 37.7% | 17 / 17 | 17 / 20 | 1M | 2M |
| Q1 2025 | 68 | 13M | 39.2% | 13 / 20 | 23 / 30 | 2M | 4M |
| Q4 2024 | 87 | 16M | 47.0% | 20 / 32 | 16 / 14 | 3M | 2M |
| Q3 2024 | 81 | 15M | 44.2% | 25 / 22 | 20 / 12 | 3M | 2M |
| Q2 2024 | 69 | 15M | 43.8% | 26 / 16 | 12 / 18 | 2M | 1M |
| Q1 2024 | 61 | 13M | 40.2% | 60 / 0 | 1 / 0 | 13M | 0M |
| Q4 2023 | 1 | 0M | 0.1% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
23 funds held JSPR in Q4 2025, 65% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of JSPR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 833,391 | 2.50% | $350.86K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 312,032 | 0.94% | $131.37K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 153,206 | 0.46% | $127.01K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 49,896 | 0.15% | $41.36K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 34,109 | 0.10% | $28.28K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 26,598 | 0.08% | $11.20K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 9,659 | 0.03% | $8.01K | 0.00% | May 31, 2026 |
| Knights of Columbus U.S. ALL CAP INDEX FUND | 155 | 0.00% | $98 | 0.00% | Jul 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -1,800 | -0.01% | -$758 | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jeetinder Singh Mahal | CEO and President, Director | 25,009 | 0.08% | Feb 10, 2026 |
| Ron Martell | President, CEO and Director | 74,118 | 0.22% | Jan 5, 2026 |
| Greg Keenan | Chief Medical Officer | – | – | Jul 23, 2026 |
| Matthew E. Ros | Chief Operating Officer | – | – | Jul 22, 2026 |
| Wenru Song | EVP, Head of R&D | 3,150 | 0.01% | Jul 22, 2026 |
| Herb Cross | Chief Financial Officer | – | – | Jan 5, 2026 |
| Edwin Jonathan Tucker | Chief Medical Officer | 400 | 0.00% | Jun 6, 2025 |
| Kurt Von Emster | Director | 5,649,733 | 16.98% | Aug 4, 2026 |
| Patrick J. Crutcher | Director | 518,331 | 1.56% | Aug 4, 2026 |
| Thomas G. Wiggans | Director | 46,000 | 0.14% | Aug 4, 2026 |
| Judith Anne Shizuru | Director | 156,901 | 0.47% | Aug 4, 2026 |
| Svetlana Lucas | Director | 20,000 | 0.06% | Aug 4, 2026 |
| Chris Nolet | Director | 32,500 | 0.10% | Jul 3, 2025 |
| Scott C. Brun | Director | – | – | Jul 3, 2025 |
| Vishal Kapoor | Director | 43,750 | 0.13% | Jul 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Svetlana Lucas Director | Sep 22, 2025 | Buy | +20,000 | $2.43 | $48.60K | 20,000 |
| Judith Anne Shizuru Director | Sep 22, 2025 | Buy | +41,000 | $2.43 | $99.63K | 156,901 |
| Ron Martell President and CEO, Director | Sep 22, 2025 | Buy | +41,000 | $2.43 | $99.63K | 74,118 |
| Thomas G. Wiggans Director | Sep 22, 2025 | Buy | +41,000 | $2.43 | $99.63K | 41,000 |
| Jeetinder Singh Mahal Chief Operating Officer | Dec 12, 2024 | Sale(10b5-1 plan) | −900 | $22.11 | $19.90K | 25,009 |
| Jeetinder Singh Mahal Chief Operating Officer | Dec 12, 2024 | Option exercise | +900 | $7.10 | $6.39K | 25,909 |
| Jeetinder Singh Mahal Chief Operating Officer | Sep 12, 2024 | Option exercise | +900 | $7.10 | $6.39K | 25,909 |
| Jeetinder Singh Mahal Chief Operating Officer | Sep 12, 2024 | Sale(10b5-1 plan) | −900 | $21.23 | $19.11K | 25,009 |
| Jeetinder Singh Mahal Chief Operating Officer | Jun 12, 2024 | Option exercise | +900 | $7.10 | $6.39K | 25,909 |
| Jeetinder Singh Mahal Chief Operating Officer | Jun 12, 2024 | Sale(10b5-1 plan) | −900 | $24.16 | $21.74K | 25,009 |
| Edwin Jonathan Tucker Chief Medical Officer | Jun 7, 2024 | Award | +400 | $4.17 | $1.67K | 400 |
| Jeetinder Singh Mahal Chief Operating Officer | Mar 12, 2024 | Option exercise | +900 | $7.10 | $6.39K | 25,909 |
| Jeetinder Singh Mahal Chief Operating Officer | Mar 12, 2024 | Sale(10b5-1 plan) | −900 | $26.44 | $23.80K | 25,009 |
| LLP Abingworth 10% owner | Feb 8, 2024 | Buy | +190,000 | $12.95 | $2.46M | 1,066,189 |
| Balaji Venkataraman 10% owner | Feb 8, 2024 | Buy | +350,000 | $12.95 | $4.53M | 1,188,500 |
| Thomas G. Wiggans Director | Nov 28, 2023 | Buy | +10,000 | $0.65 | $6.50K | 50,000 |
| Thomas G. Wiggans Director | Nov 21, 2023 | Buy | +10,000 | $0.64 | $6.40K | 40,000 |
| Thomas G. Wiggans Director | Nov 20, 2023 | Buy | +10,000 | $0.63 | $6.30K | 30,000 |
| Thomas G. Wiggans Director | Nov 17, 2023 | Buy | +10,000 | $0.60 | $6.00K | 20,000 |
| Thomas G. Wiggans Director | Nov 16, 2023 | Buy | +10,000 | $0.60 | $6.00K | 10,000 |
| William Lis Director | Oct 13, 2023 | Sale(10b5-1 plan) | −7,965 | $0.85 | $6.77K | 53,521 |
| Jeetinder Singh Mahal Chief Operating Officer | Oct 12, 2023 | Tax withholding | −37,126 | $0.85 | $31.56K | 250,097 |
| Ron Martell President, CEO & Director | Oct 12, 2023 | Tax withholding | −87,531 | $0.85 | $74.40K | 331,188 |
| Jeetinder Singh Mahal See Remarks | Jun 13, 2023 | Option exercise | +9,000 | $0.71 | $6.39K | 296,223 |
| Jeetinder Singh Mahal See Remarks | Jun 13, 2023 | Sale(10b5-1 plan) | −9,000 | $1.66 | $14.94K | 287,223 |
| Anna Louise French Director | Apr 14, 2023 | Sale | −7,000 | $1.48 | $10.36K | 23,750 |
| William Lis Director | Apr 13, 2023 | Sale | −8,500 | $1.44 | $12.24K | 61,486 |
| Kurt Von Emster Director | Apr 13, 2023 | Sale | −9,075 | $1.49 | $13.52K | 21,175 |
| Ron Martell President, CEO and Director | Apr 12, 2023 | Tax withholding | −87,531 | $1.46 | $127.80K | 418,719 |
| Jeetinder Singh Mahal See Remarks | Apr 12, 2023 | Tax withholding | −37,126 | $1.46 | $54.20K | 287,223 |
| Qiming U.S. Healthcare GP II, LLC 10% owner | Jan 27, 2023 | Buy | +2,666,666 | $1.50 | $4.00M | 8,519,648 |
| TC Group, LLC 10% owner | Jan 27, 2023 | Buy | +3,133,333 | $1.50 | $4.70M | 8,761,891 |
| Finance Ltd Roche 10% owner | Jan 25, 2023 | Sale | −75,000 | $1.89 | $141.75K | 4,549,606 |
| Judith Anne Shizuru Director | Oct 12, 2022 | Award | +29,500 | – | – | 1,159,012 |
| Kurt Von Emster Director | Oct 12, 2022 | Award | +30,250 | – | – | 30,250 |
| Jeetinder Singh Mahal See Remarks | Oct 12, 2022 | Award | +214,722 | – | – | 324,349 |
| William Lis Director | Oct 12, 2022 | Award | +29,500 | – | – | 69,986 |
| Lawrence Otto Klein Director | Oct 12, 2022 | Award | +24,500 | – | – | 24,500 |
| Ron Martell President, CEO and Director | Oct 12, 2022 | Award | +506,250 | – | – | 506,250 |
| Anna Louise French Director | Oct 12, 2022 | Award | +30,750 | – | – | 30,750 |
| Chris Nolet Director | Oct 12, 2022 | Award | +32,500 | – | – | 32,500 |
| William Lis Director | Jun 27, 2022 | Sale(10b5-1 plan) | −24,743 | $2.08 | $51.47K | 40,486 |
| William Lis Director | Jun 24, 2022 | Sale(10b5-1 plan) | −24,743 | $2.02 | $49.98K | 65,229 |
| William Lis See Remarks, Director | Mar 21, 2022 | Award | +89,972 | – | – | 89,972 |
| Howard I. Hoffen – | Sep 24, 2021 | Option exercise | +2,300,000 | – | – | 2,300,000 |
| Kenneth F. Clifford – | Sep 24, 2021 | Option exercise | +2,300,000 | – | – | 2,300,000 |
| Healthcare Holdings LLC Amplitude 10% owner | Sep 24, 2021 | Option exercise | +2,300,000 | – | – | 2,300,000 |
| Balaji Venkataraman – | Sep 24, 2021 | Option exercise | +2,300,000 | – | – | 2,300,000 |
| Paul J. Glazer 10% owner | Apr 23, 2021 | Sale | −151,719 | $9.92 | $1.51M | 895,059 |
| Paul J. Glazer 10% owner | Apr 21, 2021 | Sale | −1,164 | $9.92 | $11.55K | 1,046,778 |
| Glazer Capital, Llc 10% owner | Apr 19, 2021 | Sale | −2,060 | $9.97 | $20.54K | 1,047,942 |
| Glazer Capital, Llc 10% owner | Feb 22, 2021 | Sale | −698 | $10.50 | $7.33K | 1,050,002 |
| Glazer Capital, Llc 10% owner | Feb 19, 2021 | Sale | −2,112 | $10.50 | $22.18K | 1,050,700 |
| Glazer Capital, Llc 10% owner | Feb 18, 2021 | Sale | −10,000 | $10.45 | $104.50K | 1,052,812 |
| Glazer Capital, Llc 10% owner | Feb 5, 2021 | Sale | −212 | $10.40 | $2.20K | 1,062,812 |
| Glazer Capital, Llc 10% owner | Jan 14, 2021 | Sale | −101 | $10.40 | $1.05K | 1,063,024 |
| Glazer Capital, Llc 10% owner | Jan 8, 2021 | Sale | −10,000 | $10.25 | $102.50K | 1,063,125 |
| Glazer Capital, Llc 10% owner | Dec 30, 2020 | Sale | −75 | $10.25 | $769 | 1,073,125 |
| Glazer Capital, Llc 10% owner | Dec 29, 2020 | Sale | −18 | $10.25 | $185 | 1,073,200 |
| Glazer Capital, Llc 10% owner | Dec 28, 2020 | Sale | −10,000 | $10.20 | $102.00K | 1,073,218 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
30.82%
7M shares short
Days to cover
17.0
At 0M shares a day
Change since last report
+6.1%
From 6M shares
Short volume, 20 days
48.2%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Jasper Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 94,235 shares on Sep 30, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jeetinder Singh Mahal Executive Officer | Dec 12, 2024 | 900 | $20.22K | Dec 12, 2024 | Exercise of Stock Options Granted on 6/1/2020 |
| Jeetinder Singh Mahal Executive Officer | Sep 12, 2024 | 900 | $18.59K | Sep 12, 2024 | Exercise of Stock Options Granted on 6/1/2020 |
| Jeetinder Singh Mahal Executive Officer | Jun 12, 2024 | 900 | $21.59K | Jun 12, 2024 | Exercise of Stock Options Granted on 6/1/2020 |
| Jeetinder Singh Mahal Executive Officer | Mar 12, 2024 | 900 | $23.87K | Mar 12, 2024 | Exercise of Stock Options Granted on 6/1/2020 |
| Lis William Director | Mar 6, 2024 | 16,000 | $336.48K | Mar 6, 2024 | STOCK OPTION EXERCISE |
| William Lis Director | Oct 13, 2023 | 7,965 | $6.77K | Oct 13, 2023 | Restricted Stock Unit Vesting |
| Jeetinder Singh Mahal Executive Officer | Jun 13, 2023 | 9,000 | $204.12K | Jun 13, 2023 | Exercise of Stock Options Granted on 06/01/2020 |
| Anna Louise French Director | Apr 14, 2023 | 7,000 | $10.36K | Apr 14, 2023 | RESTRICTED STOCK |
| Kurt Von Emster Officer | Apr 13, 2023 | 9,075 | $13.52K | Apr 13, 2023 | RESTICTED STOCK |
| Lis William Director | Apr 13, 2023 | 8,500 | $12.24K | Apr 13, 2023 | RESTRICTED STOCK |
See a number that looks wrong?